Evommune (EVMN) Retained Earnings (2024 - 2026)

Evommune (EVMN) has 3 years of Retained Earnings data on file, last reported at -$242.8 million in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$242.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$242.8 million (changed N/A YoY), and the FY2025 annual result was -$221.1 million, down 45.24% from the prior year.
• Retained Earnings retreated to -$242.8 million in Q1 2026 per EVMN's latest filing, from -$221.1 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$152.2 million in Q4 2024 and troughed at -$242.8 million in Q1 2026.
• A 3-year average of -$202.2 million and a median of -$206.9 million in 2025 frame the typical range for Retained Earnings.
• On a YoY basis, Retained Earnings climbed as much as 45.24% in 2025 and fell as far as 45.24% in 2025.
• A 3-year view of Retained Earnings shows it stood at -$152.2 million in 2024, then plunged by 45.24% to -$221.1 million in 2025, then retreated by 9.8% to -$242.8 million in 2026.
• Business Quant data shows EVMN's Retained Earnings at -$242.8 million in Q1 2026, -$221.1 million in Q4 2025, and -$192.8 million in Q3 2025.